Sclerosis drug developed by Genmab brings in USD 66m to Novartis during Q2
The launch of sclerosis treatment Kesimpta is continuing to go well for Novartis, which has exceeded its financial expectations for the second quarter of this year.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT
During Q2, sclerosis treatment Kesimpta brought in USD 66m to Novartis, the company financial report released on Wednesday states.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Amgen gets Japanese authorization for migraine drug
For subscribers
Genmab surpasses 1,000 employees
For subscribers
Janssen gets FDA approval for new Darzalex combination
For subscribers
